Nearly five years ago, Kim Garland, a retired school nurse, learned she had glioblastoma—the most aggressive form of brain cancer. Surgeons removed a 6.5-centimeter tumor from her brain. Then she became one of nine patients to receive an experimental, personalized vaccine. Today, she remains cancer-free, a remarkable outcome for a disease where median survival is typically measured in months.

The vaccine, called GNOS-PV01, represents a fundamentally different approach to fighting glioblastoma. Instead of trying to kill cancer cells directly, it trains each patient's immune system to recognize and eliminate tumor cells on its own.

Here's how it works: After surgery, researchers sequence the tumor's DNA and identify up to 40 unique proteins found only on that patient's cancer cells. They then create a personalized vaccine using engineered DNA molecules that teach the immune system to recognize those specific proteins as threats. As Dr. Tanner Johanns, the primary investigator at Washington University School of Medicine, explained: the vaccine "activates the patient's immune system to recognize those proteins and eliminate the tumor cells."

The results, published May 12 in Nature Cancer, are cautiously encouraging. Two-thirds of patients showed no cancer progression at six months, compared to 40% with standard treatment. Two-thirds survived one year, again doubling historical rates. One-third survived two years.

Those numbers might not sound dramatic, but for glioblastoma—which typically kills within 15 months—they represent meaningful progress.

What makes this approach particularly clever is that it targets twice as many tumor proteins as previous cancer vaccines. That matters because glioblastoma is maddeningly adaptive. The cancer evolves rapidly, finding ways to hide from immune attack. By targeting 40 different proteins simultaneously, the vaccine makes it much harder for the tumor to escape.

The vaccine also transforms what researchers call "cold" tumors—those that hide from the immune system—into "hot" tumors that the immune system can recognize and attack.